Hypertonic saline solution for control of elevated intracranial pressure in patients with exhausted response to mannitol and barbiturates. 1999

P Horn, and E Münch, and P Vajkoczy, and P Herrmann, and M Quintel, and L Schilling, and P Schmiedek, and L Schürer
Department of Neurosurgery, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Germany.

Critically elevated intracranial pressure (ICP) represents the most important cause of morbidity and mortality in patients suffering from severe traumatic brain injury (TBI) and is a serious complication after subarachnoid hemorrhage (SAH). Thus new strategies for the control of ICP are required. Based on the evidence available hypertonic saline solution (HSS) may be a promising approach. It was therefore the aim of the present study to evaluate in a prospective manner the effects of HSS on ICP and cerebral perfusion pressure (CPP) in patients with therapy-resistant elevation of ICP. A total of 48 bolus infusions of HSS (7.5%, 2 ml kg-1 b.w.; infusion rate 20 ml min-1) were given intravenously (range 1-15 per patient) to 10 patients (age 41 +/- 6 years) with TBI and SAH. Only patients with ICP > 25 mmHg not responding to standard ICP-management protocol and plasma sodium (Na+) concentration < 150 mmol l-1 were included in the study. Within the first hour after HSS application, ICP decreased from 33 +/- 9 mmHg to 19 +/- 6 mmHg (p < 0.05) and further to 18 +/- 5 mmHg at the time of maximum effect (98 +/- 11 min post bolus). Decrease of ICP was accompanied by a rise of CPP from 68 +/- 11 mmHg to 79 +/- 11 mmHg (p < 0.05) after 1 h and further to 81 +/- 11 mmHg at the time of maximum effect. Plasma Na+ concentration was 141 +/- 6 mmol l-1 before and 143 +/- 5 mmol l-1 1 h after HSS bolus. Corresponding values for plasma osmolality were 302 +/- 11 and 308 +/- 12 mOsm l-1. When the ICP lowering effect was transient, subsequent HSS bolus was necessary 163 +/- 54 min after previous dosing. The present results indicate that repeated bolus application of HSS (7.5% NaCl, 2 ml kg-1 b.w.) is an effective measure to decrease ICP which is otherwise refractory to standard therapeutic approaches. Whether or not the therapy scheme is also suited as primary measure for the control of ICP remains to be established.

UI MeSH Term Description Entries
D006982 Hypertonic Solutions Solutions that have a greater osmotic pressure than a reference solution such as blood, plasma, or interstitial fluid. Hypertonic Solution,Solution, Hypertonic,Solutions, Hypertonic
D008297 Male Males
D008353 Mannitol A diuretic and renal diagnostic aid related to sorbitol. It has little significant energy value as it is largely eliminated from the body before any metabolism can take place. It can be used to treat oliguria associated with kidney failure or other manifestations of inadequate renal function and has been used for determination of glomerular filtration rate. Mannitol is also commonly used as a research tool in cell biological studies, usually to control osmolarity. (L)-Mannitol,Osmitrol,Osmofundin
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009994 Osmolar Concentration The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent. Ionic Strength,Osmolality,Osmolarity,Concentration, Osmolar,Concentrations, Osmolar,Ionic Strengths,Osmolalities,Osmolar Concentrations,Osmolarities,Strength, Ionic,Strengths, Ionic
D001929 Brain Edema Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6) Brain Swelling,Cerebral Edema,Cytotoxic Brain Edema,Intracranial Edema,Vasogenic Cerebral Edema,Cerebral Edema, Cytotoxic,Cerebral Edema, Vasogenic,Cytotoxic Cerebral Edema,Vasogenic Brain Edema,Brain Edema, Cytotoxic,Brain Edema, Vasogenic,Brain Swellings,Cerebral Edemas, Vasogenic,Edema, Brain,Edema, Cerebral,Edema, Cytotoxic Brain,Edema, Cytotoxic Cerebral,Edema, Intracranial,Edema, Vasogenic Brain,Edema, Vasogenic Cerebral,Swelling, Brain
D001930 Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits. Brain Lacerations,Acute Brain Injuries,Brain Injuries, Acute,Brain Injuries, Focal,Focal Brain Injuries,Injuries, Acute Brain,Injuries, Brain,Acute Brain Injury,Brain Injury,Brain Injury, Acute,Brain Injury, Focal,Brain Laceration,Focal Brain Injury,Injuries, Focal Brain,Injury, Acute Brain,Injury, Brain,Injury, Focal Brain,Laceration, Brain,Lacerations, Brain
D004234 Diuretics, Osmotic Compounds that increase urine volume by increasing the amount of osmotically active solute in the urine. Osmotic diuretics also increase the osmolarity of plasma. Osmotic Diuretic,Osmotic Diuretics,Diuretic, Osmotic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

P Horn, and E Münch, and P Vajkoczy, and P Herrmann, and M Quintel, and L Schilling, and P Schmiedek, and L Schürer
August 1998, Stroke,
P Horn, and E Münch, and P Vajkoczy, and P Herrmann, and M Quintel, and L Schilling, and P Schmiedek, and L Schürer
May 1999, Neurosurgery,
P Horn, and E Münch, and P Vajkoczy, and P Herrmann, and M Quintel, and L Schilling, and P Schmiedek, and L Schürer
January 2004, Cleveland Clinic journal of medicine,
P Horn, and E Münch, and P Vajkoczy, and P Herrmann, and M Quintel, and L Schilling, and P Schmiedek, and L Schürer
June 2017, The Nursing clinics of North America,
P Horn, and E Münch, and P Vajkoczy, and P Herrmann, and M Quintel, and L Schilling, and P Schmiedek, and L Schürer
September 2023, Indian journal of pediatrics,
P Horn, and E Münch, and P Vajkoczy, and P Herrmann, and M Quintel, and L Schilling, and P Schmiedek, and L Schürer
January 1980, Acta neurochirurgica,
P Horn, and E Münch, and P Vajkoczy, and P Herrmann, and M Quintel, and L Schilling, and P Schmiedek, and L Schürer
January 2021, Frontiers in surgery,
P Horn, and E Münch, and P Vajkoczy, and P Herrmann, and M Quintel, and L Schilling, and P Schmiedek, and L Schürer
June 2012, Continuum (Minneapolis, Minn.),
P Horn, and E Münch, and P Vajkoczy, and P Herrmann, and M Quintel, and L Schilling, and P Schmiedek, and L Schürer
January 2015, Journal of intensive care medicine,
P Horn, and E Münch, and P Vajkoczy, and P Herrmann, and M Quintel, and L Schilling, and P Schmiedek, and L Schürer
January 2023, Frontiers in surgery,
Copied contents to your clipboard!